1. Home
  2. Insights
  3. Blog
  4. Advancing endometriosis care through an innovation ecosystem

Advancing endometriosis care through an innovation ecosystem

Introduction

Endometriosis remains one of the most significant and under-recognised challenges in women’s health. Affecting an estimated 190 million women worldwide, it is associated with chronic pain, infertility, reduced quality of life, mental health burden, lost productivity and substantial healthcare costs. Many women still experience diagnostic delays of seven to ten years, driven by factors including symptom normalisation, disease heterogeneity and the historical reliance on invasive diagnostic approaches.

Yet the landscape is changing. Increased investment in women’s health, advances in diagnostics, a growing pipeline focused on disease modification and stronger cross-sector collaboration are creating new momentum. The opportunity extends beyond developing new treatments. It requires a connected ecosystem that can accelerate innovation, strengthen evidence generation, improve access and transform how endometriosis is diagnosed, treated and managed throughout a woman’s healthcare journey.

The continuing unmet need

Current treatment approaches focus primarily on symptom relief rather than altering disease progression. Hormonal therapies remain a cornerstone of care but may cause adverse effects that affect adherence and quality of life. Surgery can provide relief, although recurrence remains a common challenge.

Fertility considerations add further complexity. An estimated 30% to 50% of women experiencing infertility may have underlying endometriosis, illustrating the potential reproductive consequences of delayed diagnosis and inadequate treatment. There remains a clear need for therapies that address the biological drivers of disease rather than symptoms alone.

A growing pipeline of scientific and technological innovation

Following decades of underfunding relative to disease burden, endometriosis is attracting increased scientific and commercial interest. Research into inflammation, fibrosis, immune dysfunction, neurobiology, genetics and hormonal signalling is expanding the range of potential therapeutic targets.

Alongside established hormonal approaches, areas of investigation include immune modulation, inflammatory pathway inhibition, anti-fibrotic therapies, neuroinflammatory and pain-targeting approaches, angiogenesis inhibition, microbiome interventions, epigenetic modulation and biomarker-enabled precision medicine. This diversification reflects growing recognition of endometriosis as a heterogeneous condition with varied manifestations and treatment responses.

Investment is also extending beyond therapeutics to diagnostics, biomarker research, artificial intelligence, digital health, FemTech, real-world evidence and patient-centred research. Together, these advances could support more individualised combinations of therapeutic, diagnostic and digital solutions.

Advancing diagnostics, digital health and trial methodology

Technology-enabled innovation is reshaping endometriosis care and research. AI-powered symptom tracking, wearable technologies, virtual care platforms and advanced diagnostic tools may improve disease recognition, patient engagement and long-term monitoring while generating longitudinal data for clinical care and research.

Progress in non-invasive diagnostics is particularly important. Diagnostic confirmation has historically relied on surgical assessment, creating barriers to earlier identification and contributing to prolonged uncertainty. Blood-based biomarkers, menstrual blood testing, advanced imaging and multi-omic approaches offer potential new routes to disease identification and monitoring.

For clinical development programs, these advances could support earlier patient identification, improved stratification, more precise endpoint measurement, stronger recruitment and retention, and reduced patient burden. As these technologies mature, they may become increasingly important across both patient care and therapeutic development.

The role of Centres of Excellence

Endometriosis Centres of Excellence and broader Women’s Health Centres of Excellence are helping address fragmented care by bringing together multidisciplinary expertise in gynaecology, reproductive medicine, surgery, pain management, imaging, mental health, fertility and patient advocacy. This integrated model can support more coordinated care, shorter referral pathways and more consistent patient experiences.

Their role also extends into clinical research, translational science, real-world evidence, patient registries and investigator-led innovation. By connecting routine care with research, these centres can support more consistent standards, address geographic disparities and accelerate scientific progress.

Collaboration, regulatory science and evidence generation

Progress increasingly depends on stakeholders working across traditional boundaries. Biotechnology and pharmaceutical companies, healthcare systems, patient organisations, academic institutions, policymakers, regulators and research partners each bring different capabilities to the challenges posed by endometriosis.

Priorities include earlier patient engagement, alignment on meaningful clinical endpoints, qualification of novel biomarkers, validation of non-invasive diagnostics and digital health technologies, innovative trial methodologies, long-term outcomes assessment and real-world evidence generation. Greater collaboration in these areas can strengthen the scientific foundation for innovation and support more efficient development pathways.

No single organisation can address the complexity of endometriosis alone. The ability to connect scientific, clinical, operational, regulatory and patient perspectives is therefore becoming an important advantage in translating research into practical solutions.

The role of strategic development partnerships

As endometriosis development programs become more sophisticated, sponsors need partners that can connect therapeutic expertise with clinical, regulatory, data and operational strategy. Therapeutic centres provide one model for integrating these capabilities around a specific disease area.

For endometriosis programs, this approach can help inform study design, endpoint selection, patient engagement, evidence generation and regulatory planning. It can also help teams anticipate the practical implications of disease heterogeneity, evolving diagnostics and changing standards of care.

The value of these partnerships extends beyond efficient trial execution. By engaging early and working collaboratively, sponsors and development partners can build strategies that are scientifically robust, operationally feasible and centred on outcomes that matter to patients and healthcare systems.

Looking ahead

The future of endometriosis innovation will not be defined by a single therapy, diagnostic tool or technological breakthrough. It will depend on the strength of the ecosystem supporting their development and implementation.

Scientific advances, increased investment, improved diagnostics and stronger collaboration have created an important opportunity to reposition endometriosis as a global healthcare priority. By connecting researchers, clinicians, patients, sponsors, regulators and development partners, the community can accelerate progress towards earlier diagnosis, more effective treatment and better quality of life for women worldwide.

Connect strategy, evidence and delivery across your endometriosis program

Contact us to explore how ICON can support your endometriosis development program by connecting therapeutic insight, development strategy, evidence generation and global delivery to help align critical decisions across the asset lifecycle. 

In this section

Connect with us